Niacin 250 mg

Niacin 250 mg

21st Century4.6 (3,353 ratings)
Format:Tablet Quantity: 110 Tablet(s) · 110 servings
Goals
$4.67 $0.04 per serving
iHerbLowest$4.67iHerb$5.49

About this product

A substantial niacin amount could affect lipid metabolism if the ingredient is nicotinic acid. Calcium carbonate adds a modest mineral amount but does not broaden meaningful cardiovascular support.

The chemical form is not identified, so the tablet's likely effects cannot be established. A plain release design and no visible flush warning further weaken safe-use clarity.

The product is best considered only after confirming the form and discussing lipid-directed use with a clinician. It is poorly matched to skin support because the label does not establish niacinamide.

Who is it for
  • Adults who can verify the exact niacin form
  • Clinician-guided users considering lipid-active niacin
  • Budget-focused shoppers comfortable with a standard tablet
Best for
  • Form-dependent vitamin B3 use
  • Potential lipid support under supervision
  • Simple single-dose supplementation

Pros

  • Substantial stated niacin amount
  • Low serving cost
  • Compact formula

Cons

  • Niacin form is missing
  • No controlled-release information
  • Weak skin-goal alignment

Warnings

  • If this is nicotinic acid, pronounced flushing and itching may occur
  • Lipid-directed use may require monitoring of liver enzymes, glucose, and uric acid
  • Do not use it as a substitute for prescribed cardiovascular treatment

Product analysis

77 out of 100
A low-cost but poorly specified niacin tablet whose form must be confirmed before judging cardiovascular effects, skin relevance, or flushing risk.

AI assessment of the formula, label and price. How scoring works

Nutrient quality68

Vitamin B3 is supplied at a meaningful amount in a simple formula. The unidentified form limits assessment of absorption, flushing risk, and suitability for the intended use.

Ingredient transparency80

Most stated amounts and the serving size are clear without a conventional proprietary blend. Form ambiguity, overlapping entries, or missing non-active ingredients leave important label gaps.

Customer satisfaction72

The average rating is strong, with a very large review count supporting the signal. No detailed reviews are supplied to assess repeated complaints or intended-use experiences.

Value for money88

The long supply provides strong serving value. Added calcium and uncertainty about the niacin form reduce the formula quality.

Format
Tablet
Container
110 Tablet(s)
Per serving
$0.04
Also available
Niacin 100 mgB3 100 mg • 110 Tablet(s) • 110 servings$4.99
Customer rating
4.6 · 3,353 ratings
Report analysis

Goals

Cardiovascular Support
Cardiovascular Support
Impact
Moderate effect
C Ingredient FitF PathwaysB- EvidenceA+ Formulation Logic
Niacin · 250 mg

Niacin 250 mg lists niacin without a specific form, while the supplied marker evidence centers on nicotinic acid. The product has partial support for triglyceride metabolism, but that route does not reach the breadth comparison; calcium is an unrelated active. Its amount is below the higher reference point used for full dose support.

How this product is rated for Cardiovascular Support

Ingredient fit62

Niacin is relevant, but calcium is unrelated to the goal and the product links to other goals.
Goal fit
Niacin is the only relevant active; calcium and other goal links dilute focus.
Dose adequacy
The declared amount gives partial dose support, below the higher reference point.

Pathways17

Niacin has some link to triglyceride metabolism, but the pathway remains short of broad coverage.
Depth
Triglyceride metabolism is the strongest route, with only partial coverage.
Breadth
No target route reaches the breadth comparison's required coverage.

Evidence74

The strongest marker evidence is for nicotinic acid, with an evidence ceiling below the goal's highest.
Evidence strength
Niacin has the strongest evidence among the ingredients here, but not the goal's top ceiling.
Studied preparation
The effective ingredient amount is matched to a preparation represented in research.

Formulation logic100

Niacin needs no partner under the supplied evidence, and no conflict was identified.
Partner coverage
The credited ingredient can work alone.
Conflicts
No applicable conflict was identified in the saved facts.
Effective doses
The declared amount reaches the minimum dose comparison, though not the higher reference point.
Study evidence
Niacin Supportive 136 studies
Heart Health
Heart Health
Impact
Moderate effect
C Ingredient FitF PathwaysC EvidenceA+ Formulation Logic
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Niacin
250 mg 43
Calcium (Calcium Carbonate)
 125 mg
Gluten Free Adults 18–50
Report overview
Niacin · 250 mg OverallScore43
D+ Active Ingredient Quality & BioavailabilityF Dose, Safety & Label TransparencyD- Value
Niacin 250 mg gives a clear amount, but the label facts don't identify its chemical form. They record an NAD+ goal, yet the unknown form leaves its connection to that goal and any form-specific dose guidance unclear. The serving cost is low, but the unknown form also leaves its ingredient-specific value uncertain.
How this ingredient is rated

Active Ingredient Quality & Bioavailability50

The product's form is unspecified, so its connection to the recorded NAD+ goal and its source remain unclear.
Niacin Form & Goal Alignment
The saved facts record an NAD+ goal, but identify the niacin form only as unknown.
Precursor Source Quality
The saved facts don't identify a precursor or the chemical source.

Dose, Safety & Label Transparency37

The amount is clear, but the form-dependent dose guidance and flush profile can't be determined from the saved facts.
Clarity of Chemical Form
The label facts say only niacin and don't name its chemical form.
Form-Specific Dosage Efficacy
Although 250 mg is listed, its fit with form-specific dose guidance is unclear.
Flush Risk & Safety Labeling
The saved facts show no form-specific No-Flush label or flush warning.

Value40

The serving cost is low, but the form is unknown.
Price Per Effective Serving
The serving cost is low, though the unknown form makes its ingredient-specific value unclear.
View ingredientView products
Loading alternative details
82 Performance

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best

Sustained-release nicotinic acid provides a clearly identified cardiovascular-focused amount with controlled delivery. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, high-dose niacin can still affect the liver and requires explicit safety guidance.

80 Performance

Niacin (Vitamin B3) 500 mg

Solgar

Clearly identified nicotinic acid provides direct high-dose vitamin B3 coverage with strong cardiovascular alignment. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, the amount may cause flushing and can affect the liver, glucose, or blood pressure.

79 Performance

Niacin-Time 500 mg

Carlson

Timed-release nicotinic acid provides a transparent cardiovascular-focused dose in a long-supply format. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, controlled delivery does not remove flushing or liver-related concerns from high-dose niacin.

86 Budget

Niacinamide B-3 100 mg

Source Naturals

A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. It is among the lowest-cost supplied choices, although it does not undercut the already inexpensive original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.

82 Budget

Niacin 100 mg

Nature's Way

Clearly identified nicotinic acid supplies a modest, inexpensive vitamin B3 serving with direct form transparency. It is among the lowest-cost supplied choices, although it does not undercut the already inexpensive original, but immediate release can still cause temporary flushing and the dose is not intended for intensive cardiovascular use.

82 Budget

Niacin 100 mg

Bluebonnet

Clearly identified nicotinic acid provides a meaningful low-dose option in a simple long-supply capsule. It is among the lowest-cost supplied choices, although it does not undercut the already inexpensive original, but noticeable flushing remains possible and people sensitive to liver, glucose, or blood-pressure effects should choose carefully.

80 Value

Niacin 50 mg

Carlson

A clearly named low-dose nicotinic acid tablet provides economical and easy-to-assess vitamin B3 support. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the amount is too low for focused cardiovascular use and can still cause flushing.

85 Value

Niacin 100 mg

Source Naturals

A moderate niacinamide tablet provides clearly identified vitamin B3 without typical nicotinic-acid flushing. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form is intended for nutritional or skin support rather than lipid-focused effects.

80 Value

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar

Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form is less direct than nicotinic acid for cardiovascular purposes.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. Niacinamide: A B vitamin that improves aging facial skin appearance.
    Bissett DL; Oblong JE; Berge CA · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2005
    Randomized trial50 participantsSkin Health forNiacin
  8. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
    Hakozaki T; Minwalla L; Zhuang J; Chhoa M; Matsubara A; Miyamoto K; Greatens A; Hillebrand GG; Bissett DL; Boissy RE · The British journal of dermatology · 2002
    Randomized trial138 participantsSkin Health forNiacin
  9. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
    Mainville L; Smilga AS; Fortin PR · Journal of cutaneous medicine and surgery · 2022
    Meta-analysis3,039 participants29 studies pooledSkin Health forNiacin
  10. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
    Allen NC; Martin AJ; Snaidr VA; Eggins R; Chong AH; Fernandéz-Peñas P; Gin D; Sidhu S; Paddon VL; Banney LA; Lim A; Upjohn E; Schaider H; Ganhewa AD; Nguyen J; McKenzie CA; Prakash S; McLean C; Lochhead A; Ibbetson J; Dettrick A; Landgren A; Allnutt KJ; Allison C; Davenport RB; Mumford BP; Wong B; Stagg B; Tedman A; Gribbin H; Edwards HA; De Rosa N; Stewart T; Doolan BJ; Kok Y; Simpson K; Low ZM; Kovitwanichkanont T; Scolyer RA; Dhillon HM; Vardy JL; Chadban SJ; Bowen DG; Chen AC; Damian DL · The New England journal of medicine · 2023
    Randomized trial158 participantsSkin Health forNiacin
  11. Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide.
    Kawada A; Konishi N; Oiso N; Kawara S; Date A · The Journal of dermatology · 2008
    Randomized trial30 participantsSkin Health forNiacin
  12. A Foodborne Outbreak Traced to Niacin Overenrichment.
    Hudson PJ; Vogt RL · Journal of food protection · 2023
    Case-control study21 participantsSkin Health forNiacin
  13. Nicotinamide for Skin Cancer Chemoprevention.
    Breglio KF; Knox KM; Hwang J; Weiss R; Maas K; Zhang S; Yao L; Madden C; Xu Y; Hartman RI; Wheless L · JAMA dermatology · 2025
    Cohort study33,822 participantsSkin Health forNiacin
  14. Chemoprevention of keratinocyte carcinomas and actinic keratoses in adults who were immunocompetent: a systematic review.
    Susanto A; Morgan E; Lindsay D; Collins LG · Clinical and experimental dermatology · 2026
    Systematic review7,355 participants11 studies pooledSkin Health forNiacin
  15. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  16. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  17. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  18. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  19. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  20. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  21. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  22. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  23. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  24. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  25. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin